SR12343

SR12343, an IKK/NF-κB inhibitor, is a NF-κB essential modulator (NEMO) -binding domain (NBD) mimetic. SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO, with an IC50 of 37.02 μM for TNF-α-mediated NF-κB activation. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 can be used for research of inflammatory and degenerative diseases[1].

Product Specifications

CAS Number

[2055101-86-3]

UNSPSC

12352005

Target

IKK; NF-κB

Type

Reference compound

Related Pathways

NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/sr12343.html

Purity

99.66

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NCCC1=CC=CC(Br)=C1)CNC2=NC=C(Cl)C=C2

Molecular Formula

C15H15BrClN3O

Molecular Weight

368.66

References & Citations

[1]Zhao J, et al. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 2018 Jun 11;16 (6) :e2004663. |[2]Benhamú B, et al. New Trends in Aging Drug Discovery. Biomedicines. 2022 Aug 18;10 (8) :2006.